Psychiatry Research
Volume 144, Issue 1 , Pages 39-47 , 30 September 2006

Investigating disease susceptibility and the negative correlation of schizophrenia and rheumatoid arthritis focusing on MIF and CD14 gene polymorphisms

  • Larissa de la Fontaine

      Affiliations

    • Klinik für Psychiatrie und Psychotherapie, Nüssbaumstr. 7, Ludwig–Maximilians-Universität, D-80336 München, Germany
    • ,
  • Markus J. Schwarz

      Affiliations

    • Klinik für Psychiatrie und Psychotherapie, Nüssbaumstr. 7, Ludwig–Maximilians-Universität, D-80336 München, Germany
    • Corresponding Author InformationCorresponding author. Klinik für Psychiatrie und Psychotherapie, Ludwig–Maximilians-Universität, Nüssbaumstr. 7, D-80336 München, Germany. Tel.: +49 89 5160 2761; fax: +49 89 5160 5496.
    • ,
  • Michael Riedel

      Affiliations

    • Klinik für Psychiatrie und Psychotherapie, Nüssbaumstr. 7, Ludwig–Maximilians-Universität, D-80336 München, Germany
    • ,
  • Sandra Dehning

      Affiliations

    • Klinik für Psychiatrie und Psychotherapie, Nüssbaumstr. 7, Ludwig–Maximilians-Universität, D-80336 München, Germany
    • ,
  • Anette Douhet

      Affiliations

    • Klinik für Psychiatrie und Psychotherapie, Nüssbaumstr. 7, Ludwig–Maximilians-Universität, D-80336 München, Germany
    • ,
  • Ilja Spellmann

      Affiliations

    • Klinik für Psychiatrie und Psychotherapie, Nüssbaumstr. 7, Ludwig–Maximilians-Universität, D-80336 München, Germany
    • ,
  • Nikolaus Kleindienst

      Affiliations

    • Zentralinstitut für Seelische Gesundheit, J 5, 68159 Mannheim, Germany
    • ,
  • Peter Zill

      Affiliations

    • Klinik für Psychiatrie und Psychotherapie, Nüssbaumstr. 7, Ludwig–Maximilians-Universität, D-80336 München, Germany
    • ,
  • Herbert Plischke

      Affiliations

    • Labor für Rheumatologie und Immunologie, Pettenkoferstr. 8a, Ludwig–Maximilians-Universität, D-80336 München, Germany
    • ,
  • Rudolf Gruber

      Affiliations

    • Labor für Rheumatologie und Immunologie, Pettenkoferstr. 8a, Ludwig–Maximilians-Universität, D-80336 München, Germany
    • ,
  • Norbert Müller

      Affiliations

    • Klinik für Psychiatrie und Psychotherapie, Nüssbaumstr. 7, Ludwig–Maximilians-Universität, D-80336 München, Germany

Received 19 May 2005 ,Revised 19 December 2005 ,Accepted 6 January 2006.

References 

  1. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism. 1988;31:315–324
  2. Arolt V, Rothermundt M, Wandinger KP, Kirchner H. Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment. Molecular Psychiatry. 2000;5:150–158
  3. Ashcroft GS, Mills SJ, Lei K, Gibbons L, Jeong MJ, Taniguchi M, et al. Estrogen modulates cutaneous wound healing by downregulating macrophage migration inhibitory factor. Journal of Clinical Investigation. 2003;111:1309–1318
  4. Bacher M, Metz CN, Calandra T, Mayer K, Chesney J, Lohoff M, et al. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proceedings of the National Academy of Sciences of the United States of America. 1996;93:7849–7854
  5. Badner JA, Gershon ES. Meta-analysis of whole-genome linkage scans of bipolar disorder and schizophrenia. Molecular Psychiatry. 2002;7:405–411
  6. Baldini M, Lohman IC, Halonen M, Erickson RP, Holt PG, Martinez FD. A polymorphism in the 5′ flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. American Journal of Respiratory Cell and Molecular Biology. 1999;20:976–983
  7. Baugh JA, Chitnis S, Donnelly SC, Monteiro J, Lin X, Plant BJ, et al. A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes and Immunity. 2002;3:170–176
  8. Borda T, Gomez R, Berria MI, Sterin-Borda L. Antibodies against astrocyte M1 and M2 muscarinic cholinoceptor from schizophrenic patients' sera. Glia. 2004;45:144–154
  9. Butts C, Sternberg E. Different approaches to understanding autoimmune rheumatic diseases: the neuroimmunoendocrine system. Best practice and research. Clinical Rheumatology. 2004;18:125–139
  10. Bynoe MS, Grimaldi CM, Diamond B. Estrogen up-regulates Bcl-2 and blocks tolerance induction of naive B cells. Proceedings of the National Academy of Sciences of the United States of America. 2000;97:2703–2708
  11. Cardno AG, Marshall EJ, Coid B, Macdonald AM, Ribchester TR, Davies NJ, et al. Heritability estimates for psychotic disorders: the Maudsley twin psychosis series. Archives of General Psychiatry. 1999;56:162–168
  12. De Benedetti F, Meazza C, Vivarelli M, Rossi F, Pistorio A, Lamb R, et al. Functional and prognostic relevance of the −173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. Arthritis and Rheumatism. 2003;48:1398–1407
  13. Dobrovolskaia MA, Vogel SN. Toll receptors, CD14, and macrophage activation and deactivation by LPS. Microbes and Infection. 2002;4:903–914
  14. Donn RP, Shelley E, Ollier WE, Thomson W. A novel 5′-flanking region polymorphism of macrophage migration inhibitory factor is associated with systemic-onset juvenile idiopathic arthritis. Arthritis and Rheumatism. 2001;44:1782–1785
  15. Eaton WW, Hayward C, Ram R. Schizophrenia and rheumatoid arthritis: a review. Schizophrenia Research. 1992;6:181–192
  16. Ganguli R, Yang Z, Shurin G, Chengappa KN, Brar JS, Gubbi AV, et al. Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Research. 1994;51:1–10
  17. Ganguli R, Brar JS, Chengappa KR, DeLeo M, Yang ZW, Shurin G, et al. Mitogen-stimulated interleukin-2 production in never-medicated, first-episode schizophrenic patients. The influence of age at onset and negative symptoms. Archives of General Psychiatry. 1995;52:668–672
  18. Gorwood P, Pouchot J, Vinceneux P, Puechal X, Flipo RM, De Bandt M, et al. Rheumatoid arthritis and schizophrenia: a negative association at a dimensional level. Schizophrenia Research. 2004;66:21–29
  19. Hailman E, Lichenstein HS, Wurfel MM, Miller DS, Johnson DA, Kelley M, et al. Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14. Journal of Experimental Medicine. 1994;179:269–277
  20. Halbreich U, Kahn LS. Hormonal aspects of schizophrenias: an overview. Psychoneuroendocrinology. 2003;28(Suppl 2):1–16
  21. Hanson DR, Gottesman II. Theories of schizophrenia: a genetic-inflammatory-vascular synthesis. BMC Medical Genetics. 2005;6:7
  22. Harney SM, Newton JL, Wordsworth BP. Molecular genetics of rheumatoid arthritis. Current Opinion in Pharmacology. 2003;3:280–285
  23. Heath RG, McCarron KL, O'Neil CE. Antiseptal brain antibody in IgG of schizophrenic patients. Biological Psychiatry. 1989;25:725–733
  24. Henneberg AE, Horter S, Ruffert S. Increased prevalence of antibrain antibodies in the sera from schizophrenic patients. Schizophrenia Research. 1994;14:15–22
  25. Hubacek JA, Rothe G, Pit'ha J, Skodova Z, Stanek V, Poledne R, et al. C(−260)→T polymorphism in the promoter of the CD14 monocyte receptor gene as a risk factor for myocardial infarction. Circulation. 1999;99:3218–3220
  26. Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clinical Immunology and Immunopathology. 1997;84:223–243
  27. Jones AL, Mowry BJ, Pender MP, Greer JM. Immune dysregulation and self-reactivity in schizophrenia: do some cases of schizophrenia have an autoimmune basis?. Immunology and Cell Biology. 2005;83:9–17
  28. Kelly RH, Ganguli R, Rabin BS. Antibody to discrete areas of the brain in normal individuals and patients with schizophrenia. Biological Psychiatry. 1987;22:1488–1491
  29. Koran LM, Sox HC, Marton KI, Moltzen S, Sox CH, Kraemer HC, et al. Medical evaluation of psychiatric patients. I. Results in a state mental health system. Archives of General Psychiatry. 1989;46:733–740
  30. LeVan TD, Bloom JW, Bailey TJ, Karp CL, Halonen M, Martinez FD, et al. A common single nucleotide polymorphism in the CD14 promoter decreases the affinity of Sp protein binding and enhances transcriptional activity. Journal of Immunology. 2001;167:5838–5844
  31. Leweke FM, Gerth CW, Koethe D, Klosterkotter J, Ruslanova I, Krivogorsky B, et al. Antibodies to infectious agents in individuals with recent onset schizophrenia. European Archives of Psychiatry and Clinical Neuroscience. 2004;254:4–8
  32. Lewis CM, Levinson DF, Wise LH, DeLisi LE, Straub RE, Hovatta I, et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: schizophrenia. American Journal of Human Genetics. 2003;73:34–48
  33. Li G, Shen YC, Li YT, Chen CH, Zhau YW, Silverman JM. A case-control study of Alzheimer's disease in China. Neurology. 1992;42:1481–1488
  34. McDowell I. Alzheimer's disease: insights from epidemiology. Aging (Milano). 2001;13:143–162
  35. Moots RJ, Al-Saffar Z, Hutchinson D, Golding SP, Young SP, Bacon PA, et al. Old drug, new tricks: haloperidol inhibits secretion of proinflammatory cytokines. Annals of Rheumatic Diseases. 1999;58:585–587
  36. Morand EF. New therapeutic target in inflammatory disease: macrophage migration inhibitory factor. Internal Medicine Journal. 2005;35:419–426
  37. Morand EF, Leech M. Macrophage migration inhibitory factor in rheumatoid arthritis. Frontiers in Bioscience. 2005;10:12–22
  38. Morand EF, Leech M, Weedon H, Metz C, Bucala R, Smith MD. Macrophage migration inhibitory factor in rheumatoid arthritis: clinical correlations. Rheumatology (Oxford). 2002;41:558–562
  39. Müller N, Riedel M, Ackenheil M, Schwarz MJ. Cellular and humoral immune system in schizophrenia: a conceptual re-evaluation. World Journal of Biological Psychiatry. 2000;1:173–179
  40. Müller N, Riedel M, Scheppach C, Brandstätter B, Sokullu S, Krampe K, et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. American Journal of Psychiatry. 2002;159:1029–1034
  41. Mundo E, Altamura AC, Vismara S, Zanardini R, Bignotti S, Randazzo R, et al. MCP-1 gene (SCYA2) and schizophrenia: a case-control association study. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics. 2005;132:1–4
  42. Oken RJ, Schulzer M. At issue: schizophrenia and rheumatoid arthritis: the negative association revisited. Schizophrenia Bulletin. 1999;25:625–638
  43. Pearce BD. Schizophrenia and viral infection during neurodevelopment: a focus on mechanisms. Molecular Psychiatry. 2001;6:634–646
  44. Rubinstein G. Schizophrenia, rheumatoid arthritis and natural resistance genes. Schizophrenia Research. 1997;25:177–181
  45. Schwab SG, Hallmayer J, Albus M, Lerer B, Eckstein GN, Borrmann M, et al. A genome-wide autosomal screen for schizophrenia susceptibility loci in 71 families with affected siblings: support for loci on chromosome 10p and 6. Molecular Psychiatry. 2000;5:638–649
  46. Schwab SG, Mondabon S, Knapp M, Albus M, Hallmayer J, Borrmann-Hassenbach M, et al. Association of tumor necrosis factor alpha gene −G308A polymorphism with schizophrenia. Schizophrenia Research. 2003;65:19–25
  47. Schwarz MJ, Chiang S, Müller N, Ackenheil M. T-helper-1 and T-helper-2 responses in psychiatric disorders. Brain, Behavior, and Immunity. 2001;15:340–370
  48. Schwarz MJ, Kronig H, Riedel M, Dehning S, Douhet A, Spellmann I, et al. IL-2 and IL-4 polymorphisms as candidate genes in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience. 2006;256:72–76
  49. Silman AJ, Pearson JE. Epidemiology and genetics of rheumatoid arthritis. Arthritis Research. 2002;4(Suppl 3):S265–S272
  50. Spector TD, Silman AJ. Rheumatoid arthritis, diabetes, and schizophrenia. Lancet. 1990;335:228–229
  51. Torrey EF, Yolken RH. The schizophrenia–rheumatoid arthritis connection: infectious, immune, or both?. Brain, Behavior, and Immunity. 2001;15:401–410
  52. Vinogradov S, Gottesman II, Moises HW, Nicol S. Negative association between schizophrenia and rheumatoid arthritis. Schizophrenia Bulletin. 1991;17:669–678
  53. Wordsworth P. Rheumatoid arthritis. Current Opinion in Immunology. 1992;4:766–769
  54. Wordsworth BP, Bell JI. The immunogenetics of rheumatoid arthritis. Springer Seminars in Immunopathology. 1992;14:59–78
  55. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science. 1990;249:1431–1433
  56. Yolken R. Viruses and schizophrenia: a focus on herpes simplex virus. Herpes. 2004;11(Suppl 2):83A–88A
  57. Yu S, Nakashima N, Xu BH, Matsuda T, Izumihara A, Sunahara N, et al. Pathological significance of elevated soluble CD14 production in rheumatoid arthritis: in the presence of soluble CD14, lipopolysaccharides at low concentrations activate RA synovial fibroblasts. Rheumatology International. 1998;17:237–243
  58. Zorrilla EP, Cannon TD, Gur RE, Kessler J. Leukocytes and organ-nonspecific autoantibodies in schizophrenics and their siblings: markers of vulnerability or disease?. Biological Psychiatry. 1996;40:825–833

PII: S0165-1781(06)00014-X

doi: 10.1016/j.psychres.2006.01.006

Psychiatry Research
Volume 144, Issue 1 , Pages 39-47 , 30 September 2006

Article Tools